Levotuss (Levodropropizine)

Levodropropizine acts on sensory C‑fibers located in the airway mucosa. By inhibiting these peripheral nerve endings, it diminishes the afferent signals that trigger the cough reflex, providing relief without affecting central nervous system pathways, which distinguishes it from opioid‑based cough suppressants.

The specific dose of Levotuss is determined by the prescribing clinician based on the patient’s age, weight, severity of cough and overall health status. Healthcare providers follow local prescribing guidelines and adjust the regimen as needed; patients should follow the exact instructions given by their prescriber.

Safety data for levodropropizine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Levotuss with their healthcare provider.

To order Levotuss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Levotuss (levodropropizine) is a non‑opioid, peripheral antitussive, whereas many alternatives such as codeine or dextromethorphan act centrally on the brainstem cough center. Levodropropizine typically has a lower risk of sedation, dependence and respiratory depression, making it suitable for patients where central agents are contraindicated.

Levotuss should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or extreme temperatures to maintain its stability and efficacy.

Levotuss is taken orally. The tablet or liquid should be swallowed (or measured and ingested) according to the prescriber’s instructions, typically with or without food. Patients should not crush or chew tablets unless specifically advised, and should use a proper measuring device for liquid forms.

Serious adverse reactions, although rare, include allergic responses such as rash, urticaria, angioedema and, in extreme cases, anaphylaxis. Hepatic injury and blood dyscrasias have also been reported infrequently. Patients should seek immediate medical attention if they experience swelling of the face or throat, difficulty breathing, or signs of a severe allergic reaction.

Levotuss is contraindicated in individuals with a known hypersensitivity to levodropropizine or any of the excipients in the formulation. It should also be avoided in patients who have experienced severe allergic reactions to other peripheral antitussives. Clinicians should assess each patient’s medical history before prescribing.